Context Therapeutics Inc.
CNTX | NASDAQ
$0.47
-$0.03 (-6.02%)
At close: Aug 24, 2026, 4:00 PM ET
-6.02%
(1D)No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Market Cap $42.76M
1D Range
0.46 0.50
52W Range
0.43 3.62
Valuation (TTM)
PE -0.98
PB 1.12
EV/EBITDA -0.00
Valuation (NTM)
Forward PE N/A
Forward PEG N/A
Price Target $5.25
Cash Flow
FCF Yield -79.6%
SBC Adj. FCF Yield -83.3%
SBC Impact -4.7%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 19.7% |
-96.0%
FCF 3Y | 5Y -29.2% |
-490.7%
Returns
ROA -99.6%
ROE -82.1%
ROIC -126.8%
Financial Health
Net Cash
$42.75M
Current Ratio 5.81
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific anti...
Sector Healthcare
Industry Biotechnology
Employees 15
IPO Date Oct 20, 2021
Website www.contexttherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
5
Consensus
Buy
Price Target
$5.00
Upside
+974.34%
Buy (5)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CNTX